Biblio
Export 1352 results:
Author Title [ Type] Year Filters: First Letter Of Last Name is P [Clear All Filters]
“Circulating and Extracellular Vesicles Levels of N-(1-Carboxymethyl)-L-Lysine (CML) Differentiate Early to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 69, no. 3, pp. 751-762, 2019.
, “Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia.”, J Alzheimers Dis, vol. 65, no. 2, pp. 455-464, 2018.
, “Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia.”, J Alzheimers Dis, vol. 65, no. 2, pp. 455-464, 2018.
, “Circulating Omega-3 and Omega-6 Fatty Acids, Cognitive Decline, and Dementia in Older Adults.”, J Alzheimers Dis, vol. 95, no. 3, pp. 965-979, 2023.
, “The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.”, J Alzheimers Dis, vol. 56, no. 2, pp. 557-565, 2017.
, “The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.”, J Alzheimers Dis, vol. 56, no. 2, pp. 557-565, 2017.
, “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
, “Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care.”, J Alzheimers Dis, vol. 92, no. 3, pp. 1051-1066, 2023.
, “Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care.”, J Alzheimers Dis, vol. 92, no. 3, pp. 1051-1066, 2023.
, “Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care.”, J Alzheimers Dis, vol. 92, no. 3, pp. 1051-1066, 2023.
, “Clinical Application of Automatic Segmentation of Medial Temporal Lobe Subregions in Prodromal and Dementia-Level Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1027-1037, 2016.
, “Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes.”, J Alzheimers Dis, vol. 49, no. 3, pp. 695-705, 2016.
, “The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.”, J Alzheimers Dis, vol. 68, no. 1, pp. 311-322, 2019.
, “Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.”, J Alzheimers Dis, vol. 55, no. 2, pp. 539-549, 2017.
, “Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.”, J Alzheimers Dis, vol. 55, no. 2, pp. 539-549, 2017.
, “Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.”, J Alzheimers Dis, vol. 55, no. 2, pp. 539-549, 2017.
, “Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation.”, J Alzheimers Dis, vol. 64, no. 2, pp. 505-513, 2018.
, “The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1659-1666, 2017.
, “Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1251-62, 2016.
, “A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer's Disease Conversion in Individuals with Mild and Premild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1555-1573, 2018.
, “Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1539-1548, 2018.
, “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
, “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
, “Clinico-Neuropathological Findings in the Oldest Old from the Georgia Centenarian Study.”, J Alzheimers Dis, vol. 70, no. 1, pp. 35-49, 2019.
, “A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1347-1360, 2018.
,